P16-29. HIV Nef-specific T cells: Th1/CTL, Th2 and Th17 responses

Le résumé fourni par la source

Identification of promiscuous antigenic regions is crucial for the design of an epitope-based vaccine. Still, the quality of the responses has been under estimated in most cases when only IFN-γ is used to measure anti-HIV cellular immunity. Luminex multiplexing system allows the identification of T cell responses characteristic of T cell subtypes through their secretion of not only Th1/CTL but other important sets of cytokines, including IL-5, Il-10, Il-13, IL-21 and IL-17. We have studied the full spectrum of Nef-specific T cell memory recall responses in chronically infected HIV patients on HAART expressing a broad spectrum of HLA types. Briefly, short-term PBMC cultures were stimulated with 15-mer overlapping peptides from Nef in the presence of IL-2, conditions which favor expansion of antigen-specific T cells. Luminex analysis of the culture supernatants were used for simultaneous identification of a diverse array of peptide-specific cytokine profiles. We observed strong Th1/CTL responses against two previously described highly immunogenic regions in the central Nef sequence: Nef 67–101 and Nef 103–148. All of the 16 patients that we analyzed responded to peptides from one or both regions by secreting IFN-γ and TNF-α. However, Th2 responses (IL-5, IL-13) against peptides covering the Nef 67–97 were observed in half of the patients. This region is also able to stimulate Th1/CTL specific cells. Interestingly, we also observed high levels of IL-17 secretion in 7 out of 16 patients in response to at least one peptide, yet no specific region in the protein could be associated with IL-17 responses. In order to design new vaccines we need a deep understanding of both the quantity and quality of the responses induced by any antigen. A more complete study of T cell responses to HIV antigens is essential for the selection of epitopes that should be included in future trials.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.